GenoSolutions offers three different pharmacogenetic tests:
1. Pharmacogenetic Premium Profile
This test:
- Identifies an individual's susceptibility to adverse drug reactions
- Examines the inherited variations in genes that dictate drug response
- Identifies genetic variations that may affect the individual's ability to detoxify specific toxins including tobacco smoke and exhaust fumes
- Explores the ways these variations can be used to predict how a patient will metabolize a medication
- Uncovers genetic susceptibility to certain cancers and certain neurodegenerative disorders, Fibromyalgia.
PHASE I: CYTOCHROMEP-450
CYP1A1 CYP2A6 CYP2E1 CYP2C19
CYP1B1 CYP2D6 CYP2C9 CYP3A4
Phase I is the first line of defense in the detoxification of all environmental toxins, including pesticides, herbicides, pollutants, and solvents, pharmaceuticals and nutraceuticals, as well as many of the body's own waste products (including steroid hormones).
PHASE II: CONJUGATIONOFTOXINSANDELIMINATION
Methylation (catechol-O-methyltransferase)
COMT
Polymorphisms may lead to impaired metabolism of the catecholamine neurotransmitters (dopamine, epinephrine, and norepinephrine) and may predispose individuals to bipolar disorder, ADHD, and alcoholism.
Acetylation (N-acetyl transferase)
NAT1 NAT2
NAT detoxifies many environmental toxins, including tobacco smoke and exhaust fumes. Polymorphisms may result in slow or rapid acetylation, both associated with increased risk of lung, colon, bladder, or head & neck cancer.
Glutathione Conjugation (glutathione s-transferase)
GSTM1 GSTT1 GSTP1
GST detoxifies many water-soluble environmental toxins, including solvents, herbicides, fungicides, and heavy metals (e.g., mercury, cadmium, and lead). Defects in GST activity can contribute to fatigue syndromes and many cancers.
Oxidative Protection (superoxide dismutase)
SOD1 SOD2
Mutations affecting these antioxidant enzymes can lead to increased free radical activity and cell damage, and may increase the risk of developing neurodegenerative disorders.
2. Phramacogenetic Optimum Profile
This test:
- Identifies an individual's susceptibility to adverse drug reactions
- Examines the inherited variations in genes that dictate drug response
- Explores the ways these variations can be used to predict how a patient will metabolize a medication
PHASE I: CYTOCHROMEP-450
CYP2C19 CYP2D6 CYP2C9
Phase I is the first line of defense in the detoxification of all environmental toxins, including pesticides, herbicides, pollutants, and solvents, pharmaceuticals and nutraceuticals, as well as many of the body's own waste products (including steroid hormones).
3. Phramacogenetic Warfarin (Coumadin) Profile
The test uncovers potential genetic susceptibility to drug reactions to Warfarin (Coumadin) and recommends appropriate dosage based genetic variations of in CYP2C9 and VKORC1.
